In addition to its relevance in MGMT-silenced GBM, KL-50 may have therapeutic utility in IDH-mutant gliomas, which frequently exhibit MGMT promoter methylation and are prone to acquiring TMZ-induced MMR deficiency 15,38,91. Here, IDH1 is linked to glioma.